Go Pro

Joshua Lev Sells 3,000 Shares of electroCore (NASDAQ:ECOR) Stock

electroCore logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CFO Joshua Lev sold 3,000 electroCore shares at an average price of $9.36, generating $28,080. After the transaction, he retained 84,889 shares valued at approximately $794,561.
  • electroCore shares fell 1.9% to $9.47, while the company reported a quarterly loss of $0.33 per share—better than the $0.42 consensus estimate—and revenue of $9.45 million.
  • Institutional investors own 26.74% of the company, while analyst sentiment remains mixed with a consensus “Hold” rating and an $18 price target.
  • MarketBeat previews top five stocks to own in September.

electroCore, Inc. (NASDAQ:ECOR - Get Free Report) CFO Joshua Lev sold 3,000 shares of electroCore stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $9.36, for a total transaction of $28,080.00. Following the sale, the chief financial officer directly owned 84,889 shares in the company, valued at $794,561.04. The trade was a 3.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

electroCore Trading Down 1.9%

electroCore stock traded down $0.18 during trading hours on Tuesday, hitting $9.47. 109,294 shares of the stock traded hands, compared to its average volume of 88,973. electroCore, Inc. has a one year low of $4.41 and a one year high of $10.95. The firm's 50-day moving average price is $7.74 and its two-hundred day moving average price is $7.21. The company has a market cap of $85.42 million, a PE ratio of -5.70 and a beta of 0.93.

electroCore (NASDAQ:ECOR - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.09. The firm had revenue of $9.45 million during the quarter, compared to analyst estimates of $9.49 million. electroCore had a negative return on equity of 1,956.38% and a negative net margin of 39.96%. On average, sell-side analysts expect that electroCore, Inc. will post -1.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On electroCore

Several large investors have recently made changes to their positions in ECOR. NewEdge Advisors LLC boosted its position in shares of electroCore by 857.9% in the 1st quarter. NewEdge Advisors LLC now owns 161,955 shares of the company's stock worth $1,083,000 after purchasing an additional 145,047 shares in the last quarter. Tejara Capital Ltd bought a new position in electroCore during the 4th quarter valued at approximately $450,000. DRW Securities LLC bought a new position in electroCore during the 4th quarter valued at approximately $264,000. WealthShield Partners LLC purchased a new position in electroCore during the first quarter valued at $157,000. Finally, Cubist Systematic Strategies LLC purchased a new position in electroCore during the first quarter valued at $153,000. 26.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of electroCore in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $18.00.

Check Out Our Latest Report on ECOR

About electroCore

(Get Free Report)

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company's lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.

Further Reading

Insider Buying and Selling by Quarter for electroCore (NASDAQ:ECOR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in electroCore Right Now?

Before you consider electroCore, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and electroCore wasn't on the list.

While electroCore currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines